Brokers name 2 strong ASX 200 shares to buy now

These shares are among the top picks on the benchmark ASX 200 index according to analysts.

| More on:
A business woman flexes her muscles overlooking a city scape below.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There are a total of 200 ASX shares to choose from on the benchmark S&P/ASX 200 Index (ASX: XJO).

But not all of them are necessarily good investments. So, which ones are?

Luckily, brokers have done the hard work for you and picked out two they rate highly. They are as follows:

ALS Ltd (ASX: ALQ)

The team at Morgans thinks that this testing services company could be an ASX 200 share to buy.

The broker likes ALS due to the positive outlook for its Life Sciences business and exposure to the commodities cycle. It believes a positive part of the latter may not be too far away.

ALQ looks poised to benefit from margin recovery in Life Sciences as well as a cyclical volume recovery in Commodities. Timing around the latter is less certain though our analysis indicates we may not be too far away (3- 12 months).

In addition, commodity prices are supportive with both gold & copper around all-time highs at US$2650/oz & US$4.50/lb respectively. Investment view: ALQ is the dominant global leader in geochemistry testing (~50% market share), which is highly cash generative and is little chance of being competed away for a variety of reasons. The excess capital from Commodities is used to fund capital driven earnings growth in Life Sciences.

Morgans has put an add rating and $15.50 price target on its shares.

CSL Ltd (ASX: CSL)

Another ASX 200 share that brokers are bullish on is biotechnology giant CSL.

Bell Potter is bullish on the company's outlook, believing that it can deliver double digit earnings growth over the medium term even if not all of its businesses are firing on all cylinders.

This is thanks largely to the key CSL Behring business, which is expected to do the heavy lifting in the near term. It explains:

CSL is a global biotechnology company holding the #1 or #2 position in its three key markets: (1) plasma-derived therapies (Behring), (2) flu vaccines (Seqirus) and (3) iron products (Vifor). Behring is CSL's largest division (72% of revenue) and we expect it will continue to do the heavy lifting in the near-term, both in topline growth and margin expansion.

CSL's FY25 revenue guidance of 5%-7% (BPe 6.5%) is comprised of "high single digit" growth for Behring and "flattish" growth for Seqirus and Vifor. Behring's more favourable outlook, coupled with its gross margin recovery to pre-pandemic levels (which we expect in FY28), results in confidence that CSL will be able to achieve its guidance of "annual double-digit earnings growth" over the mid-term, despite more challenging near-term prospects for Seqirus and Vifor.

Bell Potter currently has a buy rating and $345.00 price target on the ASX 200 share.

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Blue Chip Shares

A fit man flexes his muscles, indicating a positive share price movement on the ASX market
Blue Chip Shares

3 strong ASX 200 blue chip stocks to buy with $2,000 in December

These blue chips have been given the thumbs up from analysts.

Read more »

A share market analyst looks at his computer screen in front of him showing ASX share price movements
Blue Chip Shares

Analysts name 3 strong blue chip ASX 200 shares to buy in December

Let's see which blue chips are bring tipped as buys by analysts right now.

Read more »

three businessmen high five each other outside an office building with graphic images of graphs and metrics superimposed on the shot.
Blue Chip Shares

Buy these 3 high-quality ASX 200 blue chip shares in December

Analysts think these high-quality shares are buys right now. Let's see what they are saying.

Read more »

Two people comparing and analysing material.
Blue Chip Shares

Are Woodside or CBA shares a better buy?

Here’s how I’d compare these two major ASX blue chips.

Read more »

A group of young people lined up on a wall are happy looking at their laptops and devices as they invest in the latest trendy stock.
Blue Chip Shares

Why these ASX 200 blue chip shares could generate big returns

Brokers think these shares are could be dirt cheap at current levels.

Read more »

Man sits smiling at a computer showing graphs
Blue Chip Shares

3 ASX shares Australians can buy and hold for the next decade

Analysts think these high quality stocks could be in the buy zone right now.

Read more »

2 women looking at phone
Blue Chip Shares

3 high quality blue chip ASX 200 shares to buy in November

Here are a few blue chip shares that have been rated as buys this month by analysts.

Read more »

A businessman lights up the fifth star in a lineup, indicating positive share price for a top performer
Blue Chip Shares

2 of the highest-quality blue chip ASX 200 stocks money can buy

Analysts think these blue chips are top buys for investors right now. But why?

Read more »